Molecular docking and molecular dynamics mimetics showed that Daidzein docked well with ENO3, and further in vitro experiments indicated that Daidzein may ameliorate MASLD through the PPAR/ENO3 signaling pathway. The gene discussed is ENO3; the disease is metabolic dysfunction-associated steatotic liver disease.